血管生成拟态在恶性肿瘤的研究进展

摘要/Abstract

摘要：血管生成拟态(VM)一种存在于恶性肿瘤的血液供应模式，乳腺恶性肿瘤VM的形成机制十分复杂。肿瘤细胞的可塑性和多种分子的调节在VM形成机制中起重要作用，同时缺氧微环境及微小RNA（miRNA)与VM的发生和发展具有相关性。缺氧微环境及miRNA与乳腺恶性肿瘤VM关系尤为密切，将有望成为乳腺癌临床研究中重要的诊断及判断预后的指标。

关键词:乳腺癌,血管内皮生长因子类,缺氧诱导因子1,α亚基,微RNAs,血管生成拟态

Abstract:Vasculogenic mimicry (VM) is one of the blood supply patterns in malignant tumor, and the molecular mechanism of breast malignant tumor VM is complicated. The plasticity of tumor cells and variety of molecules regulation play important roles in the mechanism of VM. At the same time, the hypoxic microenvironment and microRNA (miRNA) are associated with the occurrence and development of VM, especially in breast malignant tumor, and they are expected to become important diagnostic and prognostic indicators in breast cancer.

Key words:Breast neoplasms,Vascular endothelial growth factors; ,Hypoxia inducible factor 1, alpha subunit,MicroRNAs,Vasculogenic mimicry

李丕嵩, 李建一, 张文海. 血管生成拟态在恶性肿瘤的研究进展[J]. 国际肿瘤学杂志, 2014, 41(11): 824-827.

LI Pi-Song, LI Jian-Yi, ZHANG Wen-Hai. Vasculogenic mimicry in cancer[J]. Journal of International Oncology, 2014, 41(11): 824-827.

参考文献

［1］ Karroum A, Mirshahi P, Faussat AM, et al. Tubular network formation by adriamycinresistant MCF7 breast cancer cells is closely linked to MMP9 and VEGFR2/VEGFR3 overexpressions［J］. Eur J Pharmacol， 2012, 685(13):17. ［2］ Lee CH, Wu YT, Hsieh HC, et al. Epidermal growth factor/heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem/progenitor cel［J］. Biochimie， 2014, 104:117126. ［3］刘见荣，侯风刚. 肿瘤血管生成拟态研究新进展［J］. 现代肿瘤医学， 2013， 21(4):898902. ［4］ Maes H, Van Eygen S, Krysko DV, et al. BNIP3 supports melanoma cell migration and vasculogenic mimicry by orchestrating the actin cytoskeleton［J］. Cell Death Dis， 2014, 5: e1127. ［5］ Yao XH, Ping YF, Bian XW. Contribution of cancer stem cells to tumor vasculogenic mimicry［J］. Protein Cell， 2011, 2(4):266272. ［6］ Lathia JD, Gallagher J, Heddleston JM, et al. Integrin alpha 6 regulates glioblastoma stem cells［J］. Cell Stem Cell， 2010, 6(5):421432. ［7］ Ding YP, Yang XD, Wu Y, et al. Autophagy promotes the survival and development of tumors by participating in the formation of vasculogenic mimicry［J］. Oncol Rep， 2014, 31(5):23212327. ［8］ Mao XG, Xue XY, Wang L, et al. CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia［J］. Neuro Oncol， 2013, 15(7):865879. ［9］ Du J, Sun B, Zhao X, et al. Hypoxia promotes vasculogenic mimicry formation by inducing epithelialmesenchymal transition in ovarian carcinoma［J］. Gynecol Oncol， 2014, 133（3）： 575583. ［10］ Fang M, Peng CW, Liu SP, et al. In vitro invasive pattern of hepatocellular carcinoma cell line HCCLM9 based on threedimensional cell culture and quantum dots molecular imaging［J］. J Huazhong Univ Sci Technolog Med Sci，2013, 33(4):520524. ［11］ Vartanian AA. Signaling pathways in tumor vasculogenic mimicry［J］. Biochemistry (Mosc)， 2012， 77(9):10441055. ［12］ Jana D, Sarkar DK, Ganguly S, et al. Role of Cyclooxygenase 2 (COX2) in Prognosis of Breast Cancer［J］. Indian J Surg Oncol， 2014， 5(1):5965. ［13］ Liu XM，Zhang QP, Mu Y， et al. Clinical significance of vasculogenic mimicry in human gliomas［J］. J Neurooncol, 2011, 105(2):173179. ［14］ Casas E, Kim J, Bendesky A, et al. Snail2 is an essential mediator of Twist1induced epithelial mesenchymal transition and metastasis［J］. Cancer Res， 2011, 71(1):245254. ［15］ Zhu LF, Hu Y, Yang CC, et al. Snail overexpression induces an epithelial to mesenchymal transition and cancer stem celllike properties in SCC9 cells［J］. Lab Invest， 2012, 92(5):744752. ［16］ Sun D, Sun B, Liu T, et al. Slug promoted vasculogenic mimicry in hepatocellular carcinoma［J］. J Cell Mol Med， 2013, 17(8):10381047. ［17］ El Hallani S, Boisselier B, Peglion F, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry［J］. Brain，2010， 133(4):973982. ［18］ Larson AR, Lee CW, Lezcano C, et al. Melanoma spheroid formation involves lamininassociated vasculogenic mimicry［J］. Am J Pathol，2014， 184(1):7178. ［19］ Sher I, Adham SA, Petrik J, et al. Autocrine VEGFA/KDR loop protects epithelial ovarian carcinoma cells from anoikis［J］. Int J Cancer, 2009， 124(3):553561. ［20］张凤梅，李胜水，许华，等. 乳腺癌血管生成拟态及其与VEGF表达相关性的研究［J］. 现代肿瘤医学, 2012， 20(11):23242327. ［21］ Chai DM, Bao ZQ, Hu JG, et al. Vasculogenic mimicry and aberrant expression of HIFlalpha/Ecad are associated with worse prognosis of esophageal squamous cell carcinoma［J］. J Huazhong Univ Sci Technolog Med Sci， 2013, 33(3):385391. ［22］ Misra RM, Bajaj MS， Kale V. Vasculogenic mimicry of HT1080 tumour cells in vivo: critical role of HIF1alphaneuropilin1 axis［J］. PLoS One， 2012， 7(11):e50153. ［23］ Li JY, Zhang Y, Zhang WH, et al. Differential distribution of miR20a and miR20b may underly metastatic heterogeneity of breast cancers［J］. Asian Pac J Cancer Prev， 2012, 13(5):19011906. ［24］ Wang J, Gu Z, Ni P, et al. NFkappaB P50/P65 heterodimer mediates differential regulation of CD166/ALCAM expression via interaction with micoRNA9 after serum deprivation, providing evidence for a novel negative autoregulatory loop［J］. Nucleic Acids Res，2011, 39(15):64406455. ［25］ Song Y, Mu L, Han X, et al. MicroRNA9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression［J］. J Neurooncol，2013, 115(3):381390. ［26］ Wu N, Zhao X, Liu M, et al. Role of microRNA26b in glioma development and its mediated regulation on EphA2［J］. PLoS One， 2011， 6(1):e16264. ［27］ Shevde LA, Metge BJ, Mitra A, et al. Spheroidforming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsamiR2995p regulated de novo expression of osteopontin［J］. J Cell Mol Med，2010， 14(6B):16931706. ［28］ Weng C, Dong H, Chen G, et al. miR4093p inhibits HT1080 cell proliferation, vascularization and metastasis by targeting angiogenin［J］. Cancer Lett， 2012, 323(2):171179.

[1]	龚艳, 陈洪雷.微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[2]	邵建强, 王鹏, 白杰, 李会欣, 王遵义, 徐志宏.银杏叶提取物诱导乳腺癌MCF-7细胞线粒体自噬的机制研究[J]. 国际肿瘤学杂志, 2024, 51(2): 65-72.
[3]	潘书兰, 刘畅, 贺平.福瑞替尼对三阴性乳腺癌血管生成、肿瘤生长及IRE1-ASK1-JNK通路的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 457-462.
[4]	徐凡, 王婧, 毛宁, 王世雄, 李金茂.戈沙妥珠单抗治疗晚期三阴性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 508-510.
[5]	李彬, 张桂芳, 周林静, 杨小冬, 何秋立, 贾思思, 黄普超, 梁嘉欣.三阴性乳腺癌中PIK3CA基因状态与临床特征及预后的关系[J]. 国际肿瘤学杂志, 2023, 50(5): 263-267.
[6]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳.沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[7]	谢露露, 丁江华.免疫治疗在晚期三阴性乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(11): 672-676.
[8]	吴家宜, 陈柯羽, 邵喜英, 王晓稼.CDK4/6抑制剂通过调控三阴性乳腺癌免疫微环境促进抗肿瘤免疫的机制研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 362-365.
[9]	周仁邦, 张仲传, 许志远, 朱勋兵.miR-219a-5p通过负调控HMGA2抑制骨肉瘤U2OS细胞增殖、侵袭和迁移[J]. 国际肿瘤学杂志, 2022, 49(4): 193-198.
[10]	金嘉会, 陈存海, 马学真.放射相关miRNA在乳腺癌放疗中的作用[J]. 国际肿瘤学杂志, 2022, 49(12): 735-738.
[11]	井文君, 赵文文, 冯青青, 赵文飞, 赵丽丽, 张雪, 魏红梅.miR-34家族用于胃癌治疗的分子基础及临床前景[J]. 国际肿瘤学杂志, 2022, 49(11): 681-686.
[12]	王孟超, 陈立伟, 孔凡铭.戈沙妥珠单抗治疗三阴性乳腺癌的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 619-622.
[13]	罗丽云, 赖灿辉, 梁仁佩, 杨爱武, 林志敏.晚期胃癌中miR-524-5p与SOX9表达的相关性及其对化疗疗效和预后的影响[J]. 国际肿瘤学杂志, 2022, 49(1): 45-50.
[14]	刘佩, 蒲嘉泽, 黄雯, 汪斐.吉非替尼敏感与耐药NSCLC患者miR-200c、miR-19a、miR-155表达差异及其对患者预后的影响[J]. 国际肿瘤学杂志, 2021, 48(7): 409-414.
[15]	王阳, 刘芊, 龙辉, 吴清明.结直肠癌标志物粪便检测的研究现状[J]. 国际肿瘤学杂志, 2021, 48(7): 441-444.